Celldex Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $22.00K | $-0.94 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $0 | $-1.18 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | After market close | $100.00K | $-1.22 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | $0 | $-1.01 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $700.00K | $-0.85 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $700.00K | $-0.81 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | $1.20M | $-0.71 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $3.20M | $-0.64 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 26, 2024 | Before market open | – | – | – |
Press releases
Announcements Celldex Therapeutics filed with the SEC
Celldex Announces Positive Results from Phase
Other events · EX-99.1 to Form 8-K
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Pricing of $300 Million Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports Results from Phase 2 Study of
Other events · EX-99.1 to Form 8-K
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
of Upsized $400 Million Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
of Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Therapeutics Announces Appointment of
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K